BR-790 is under clinical development by Shanghai Gefeimu Biomedical Technology and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BR-790’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-790 is under development for the treatment of advanced solid tumor including non-small cell lung cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck cancer squamous cell carcinoma. It is administered through oral route as a tablet.
Shanghai Gefeimu Biomedical Technology overview
Shanghai Gefeimu Biomedical Technology (Gefeimu Biomedical) operate in healthcare sector. Gefeimu Biomedical is headquartered in Shanghai, China.
For a complete picture of BR-790’s drug-specific PTSR and LoA scores, buy the report here.